Life SciencesLiability
SpecialtyStandard / Universal

503B Outsourcing Facility FDA Registration COI

What this clause says

Vendor warrants its current registration as a 503B Outsourcing Facility with the FDA and shall provide a Certificate of Insurance reflecting cGMP-aligned property coverage, products liability of not less than $5,000,000 per occurrence, and product recall extension covering FDA-mandated recalls.

What this means in plain English

503B outsourcing facilities are FDA-registered drug manufacturers under section 503B of the FDCA. Hospital purchase contracts with 503Bs typically require cGMP-aligned property coverage, $5M-$10M products liability, and FDA-specific recall extensions.

What it means for a CDMO program

A 503B outsourcing facility carrying a generic compounding-pharmacy program will fail hospital procurement insurance reviews. The cGMP environment changes the property exposure (validation losses, batch losses, cleanroom contamination), and large-batch production amplifies recall stakes vs. patient-specific 503A operations.

How this evaluates

The Decoder applies these rules in order; the first match wins.

  • fda503 b › registered is set → Compliant: FDA-registered 503B status documented.
  • fda503 b › registered is not set → Gap: No FDA 503B registration documented — required for outsourcing-facility hospital contracts.

See this in your MSA

Pre-loaded with this clause selected.

Run the Decoder

Related clauses

Questions about specialty

503B Outsourcing Facility FDA Registration COI — common questions

What is the difference between 503A and 503B?

+

503A pharmacies compound for specific patients with prescriptions; 503B outsourcing facilities are FDA-registered manufacturers producing in bulk for hospitals without patient-specific prescriptions. Different regulatory regimes, different insurance requirements.

Do hospitals require specific insurance for 503B suppliers?

+

Yes. Hospital purchase contracts with 503Bs typically require $5M-$10M products liability, cGMP-aligned property coverage, and recall extensions explicitly written for FDA-registered drug manufacturers.

How is 503B insurance different from 503A insurance?

+

The cGMP manufacturing environment changes property exposures (validation losses, batch losses, cleanroom contamination) and the bulk-manufacturing scale amplifies recall stakes. Generic compounding-pharmacy programs are inadequate.